Expert Discusses Durvalumab and Expanding Role of Immunotherapy in NSCLC – OncLive
OncLive |
Expert Discusses Durvalumab and Expanding Role of Immunotherapy in NSCLC
OncLive In an interview with OncLive, Marina C. Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discussed the evolving paradigm of immunotherapy in NSCLC, with a specific focus on durvalumab and … |
